<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003520</url>
  </required_header>
  <id_info>
    <org_study_id>MEDI4736-DLBCL-001</org_study_id>
    <secondary_id>2015-005173-20</secondary_id>
    <nct_id>NCT03003520</nct_id>
  </id_info>
  <brief_title>A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF DURVALUMAB IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE (R-CHOP) OR WITH LENALIDOMIDE PLUS R CHOP (R2 CHOP) IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical
      activity, predictive biomarkers and pharmacokinetics/ pharmacodynamics of durvalumab in
      combination with R-CHOP (Arm A) or R2-CHOP (Arm B), followed by durvalumab consolidation
      therapy in previously untreated subjects with high-risk DLBCL.

      Patients with non-ABC subtype (determined by gene expression profiling) will be allocated to
      Arm A while patients with ABC (activated B-cell type) subtype will be allocated to Arm B.
      Approximately 120 patients may be enrolled and assigned into the appropriate treatment arms
      dependent upon their cell of origin status.

      Induction treatment with R-CHOP (± Lenalidomide) will last for a total of up to 6 to 8
      treatment cycles (21 days cycle), and the total time on study treatment, including durvalumab
      consolidation, will last up to 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is conducted in patients with previously untreated, high-risk Diffuse
      Large B-cell Lymphoma (DLBCL). Patients with high-risk DLBCL typically have insufficient
      therapeutic outcomes. Therefore, the addition of novel agents to the currently used induction
      therapy (R-CHOP backbone) is a rational approach to improve therapeutic outcomes in this
      disease setting.

      Based on pre-clinical and clinical observations, it is hypothesized that durvalumab will have
      activity in DLBCL because the PD 1/PD L1 pathway is involved in the pathophysiology of DLBCL.
      In particular, the addition of durvalumab may significantly augment the anti-tumor activity
      of R-CHOP against high-risk DLBCL subtypes.

      There are different subtypes of DLBCL which are distinguished by their Cell of Origin (ABC,
      GCB, unclassifiable). About a third of DLBCL is of the ABC subtype and as those patients have
      a worse outcome when treated with R-CHOP, lenalidomide plus R-CHOP (R2-CHOP) will be used for
      patients with the ABC subtype.

      The safety of durvalumab has already been explored. However, as there is limited clinical
      experience with durvalumab in DLBCL, the study is divided into two stages:

        -  A Safety Run-in Stage to evaluate the safety of the treatment combinations until at
           least 10 subjects are included in each of the two treatment arms for a total of 20
           subjects

        -  An Expansion Stage to analyze the clinical activity of the treatment combinations in up
           to 100 additional subjects
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival at 24 months</measure>
    <time_frame>Up to 24 months after last patient is enrolled</time_frame>
    <description>Subjects who have not experienced disease progression or death within 24 months after start of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>Up to 15 months after last patient is enrolled</time_frame>
    <description>Number of participants with adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to study treatment in biomarker-defined subpopulations</measure>
    <time_frame>Up to 24 months after last patient is enrolled</time_frame>
    <description>Identification and development of biomarkers predictive of clinical response to study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 1125 mg intravenously (IV) on Day 1 of each 21-day cycle in combination with 6 to 8 cycles R-CHOP (IV rituximab, doxorubicin, vincristine, and cyclophosphamide on Day 1; daily oral/IV prednisone/prednisolone from Day 1 to 5) followed by durvalumab monotherapy for up to a total of 12 months after start of study treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 1125 mg IV on Day 1 of each 21-day cycle in combination with 6 to 8 cycles R2-CHOP (IV rituximab, doxorubicin, vincristine and cyclophosphamide on Day 1; daily oral/IV prednisone/prednisolone from Day 1 to 5; daily oral lenalidomide 15 mg from Day 1 to 14) from Cycle 2 until end of induction therapy (Cycle 6 or Cycle 8), or starting Cycle 1 if ABC subtype is identified prior to Cycle 1 Day 1 (C1D1) followed by durvalumab monotherapy for up to a total of 12 months after start of study treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone</description>
    <arm_group_label>Arm A (non-ABC DLBCL): Durvalumab in combination with R-CHOP</arm_group_label>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide</description>
    <arm_group_label>Arm B (ABC DLBCL): Durvalumab in combination with R2-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CD20+Diffuse Large B-Cell Lymphoma.

          2. Ann Arbor stage 3 or 4 or stage 2 with bulky disease

          3. High or high-intermediate disease risk.

          4. No prior anti-lymphoma treatment.

          5. Subject is willing and able to undergo biopsy.

          6. Investigator considers R-CHOP immunochemotherapy appropriate.

          7. ECOG performance status of 0-2.

          8. Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 x 10^9/L,
             platelet count ≥ 75 x 10^9/L, hemoglobin ≥ 10.0 g/dL).

          9. Adequate biochemistry laboratory results (AST/SGOT and ALT/SGPT ≤ 3.0 x upper limit of
             normal; bilirubin ≤ 2.0 mg/dL; creatinine clearance of ≥ 40 mL/min).

         10. Bi-dimensionally measurable disease (&gt; 2.0 cm).

         11. Subject is using effective contraception.

        Exclusion Criteria:

          1. Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.

          2. Composite lymphoma or transformed lymphoma.

          3. Primary or secondary Central Nervous System involvement by lymphoma.

          4. Seropositive or active viral infection with hepatitis B virus, human immunodeficiency
             virus or hepatitis C virus.

          5. History of other malignancies, unless disease-free for ≥ 5 years.

          6. Left ventricular ejection fraction &lt; 50%.

          7. Peripheral neuropathy ≥ Grade 2.

          8. Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.

          9. High risk of developing thromboembolic events, who are unwilling to take venous
             thromboembolism prophylaxis.

         10. Active or prior documented autoimmune or inflammatory disorders within the past 3
             years.

         11. Current or prior use of immunosuppressive medication within 28 days before start of
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Manzke, Medical Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology Hematology Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Medical University Dep. of Internal Medicine</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna Internalmedicine 1, Hematology</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Sygehus</name>
      <address>
        <city>Arhus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense C</city>
        <zip>DK5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Diffuse-large B-Cell Lymphoma</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Anti-PD-L1 Antibody</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Immune Checkpoint</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Prednisone/Prednisolone</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

